Tiziana Life Sciences PLC Grant of options - Director's dealing (4431P)

TIDMTILS

RNS Number : 4431P

Tiziana Life Sciences PLC

31 August 2017

Tiziana Life Sciences PLC

("Tiziana" or the "Company")

Grant of options - Director's dealing

London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that the Remuneration Committee proposed and the Board has awarded the following options on 30 August 2017.

Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer, has been awarded options over 400,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 159.5 pence per share. The options will vest in equal tranches over four years beginning on the date of grant. Dr Shailubhai already holds 300,000 options at an exercise price of 50p pursuant to an award made on 25 June 2014 (of which 200,000 options are vested and 100,000 remain subject to vesting conditions).

A further 168,000 options over ordinary shares in the capital of the Company were granted by the Company to staff members on the same terms and on the same date.

The Company's issued share capital comprises 123,827,938 ordinary shares of 3p each.

Including the grants noted above, the Company has granted options over a total of 10,717,403 ordinary shares of which 4,752,500 are vested at exercise prices between 15p and GBP1.25p per share and 5,964,903 remain subject to vesting conditions (at potential exercise prices ranging from 15p to GBP1.925 per share). In addition warrants to subscribe for a total of 4,239,579 ordinary shares at exercise prices between 50p and GBP2.50 are outstanding.

Therefore the fully diluted issued share capital of the Company is 138,784,920 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

 
Tiziana Life Sciences plc 
 Gabriele Cerrone, Chairman and founder            [phone] 
Cairn Financial Advisers LLP (Nominated adviser) 
 Liam Murray / Jo Turner / Richard Nash            [phone] 
Beaufort Securities Limited (Broker) 
 Saif Janjua                                       [phone] 
FTI Consulting 
 Simon Conway / Natalie Garland-Collins            [phone] 
 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

For more information go to http://www.tizianalifesciences.com

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
--------------------------------------------------------------------- 
 1      Details of the person discharging managerial 
         responsibilities/person closely associated 
-----  -------------------------------------------------------------- 
 a.     Name                           Dr Kunwar Shailubhai 
                                      ------------------------------- 
 2      Reason for 
         notification 
-----  -----------------------------  ------------------------------- 
 a.     Position/Status                Chief Executive Officer 
-----  -----------------------------  ------------------------------- 
 b.     Initial notification/          31 August 2017 
         Amendment 
-----  -----------------------------  ------------------------------- 
 3      Details of the issuer, emission allowance 
         market participant, auction platform, auctioneer 
         or auction monitor 
       -------------------------------------------------------------- 
 a.     Name                           Tiziana Life Sciences plc 
-----  -----------------------------  ------------------------------- 
 b.     LEI 
-----  -----------------------------  ------------------------------- 
 4      Details of the transaction(s): section to 
         be repeated for (i) each type of instrument; 
         (ii) each type of transaction; (iii) each 
         date; and (iv) each place where transactions 
         have been conducted 
-----  -------------------------------------------------------------- 
 a.     Description                    Option 
         of the financial 
         instrument,                    GB00BKWNZY55 
         type of instrument 
 
         Identification 
         Code 
-----  -----------------------------  ------------------------------- 
 b.     Nature of the                  Grant of options 
         transaction 
-----  -----------------------------  ------------------------------- 
 
 c.     Price(s) and                   Price(s)       Volume(s) 
         volume(s) 
-----  -----------------------------  -------------  ------------- 
                                       159.5p         400,000 
                                      -------------  ------------- 
 
        Aggregated 
         information 
 
         - Aggregated 
         Volume                          400,000 
 
 d.      - Price                         159.5p 
-----  -----------------------------  ------------------------------- 
 e.     Date of the                    31 August 2017 
         transaction 
-----  -----------------------------  ------------------------------- 
 f.     Place of the                   XLON 
         transaction 
-----  -----------------------------  ------------------------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHGMGFRGMDGNZM

(END) Dow Jones Newswires

August 31, 2017 06:07 ET (10:07 GMT)